Cantor Fitzgerald Reaffirms Their Buy Rating on Eupraxia Pharmaceuticals (EPRX)
In a report released today, Kristen Kluska from Cantor Fitzgerald maintained a Buy rating on Eupraxia Pharmaceuticals, with a price target of $11.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
According to TipRanks, Kluska is a 5-star analyst with an average return of 34.3% and a 47.74% success rate. Kluska covers the Healthcare sector, focusing on stocks such as Monopar Therapeutics Inc, Celldex, and Taysha Gene Therapies.
Currently, the analyst consensus on Eupraxia Pharmaceuticals is a Strong Buy with an average price target of C$14.52.
Based on Eupraxia Pharmaceuticals’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of C$8.74 million. In comparison, last year the company had a GAAP net loss of C$6.01 million
Based on the recent corporate insider activity of 9 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of EPRX in relation to earlier this year.
Read More on TSE:EPRX:
Disclaimer & DisclosureReport an Issue
- Eupraxia Pharmaceuticals Reports Promising 52-Week Data for EoE Treatment
- Eupraxia Pharmaceuticals’ EP-104GI shows efficacy in follow-up esophagitis data
- Eupraxia Pharmaceuticals: Buy Rating Backed by Strong Pipeline Advancements and Robust Financial Position
- Eupraxia Pharmaceuticals Releases Q3 2025 Financial Results
- Eupraxia Pharmaceuticals Advances EoE Treatment with EP-104GI Trial
